345 related articles for article (PubMed ID: 19586938)
41. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.
van Dongen JJ; Macintyre EA; Gabert JA; Delabesse E; Rossi V; Saglio G; Gottardi E; Rambaldi A; Dotti G; Griesinger F; Parreira A; Gameiro P; Diáz MG; Malec M; Langerak AW; San Miguel JF; Biondi A
Leukemia; 1999 Dec; 13(12):1901-28. PubMed ID: 10602411
[TBL] [Abstract][Full Text] [Related]
42. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
Voskova D; Schoch C; Schnittger S; Hiddemann W; Haferlach T; Kern W
Cytometry B Clin Cytom; 2004 Nov; 62(1):25-38. PubMed ID: 15468339
[TBL] [Abstract][Full Text] [Related]
43. Minimal residual disease monitoring cannot fully replace bone marrow morphology in assessing disease status in pediatric acute lymphoblastic leukemia.
Rathe M; Preiss B; Marquart HV; Schmiegelow K; Wehner PS
APMIS; 2020 May; 128(5):414-419. PubMed ID: 32108963
[TBL] [Abstract][Full Text] [Related]
44. [Fluorescence quantitative PCR detection of WT1 gene expression in peripheral blood of patients with acute leukemias and its clinical implications].
Bai B; Wang HW; Xu YQ; Yang HN; Qiao ZH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):610-4. PubMed ID: 16129044
[TBL] [Abstract][Full Text] [Related]
45. Detection of minimal residual disease in acute leukemia.
Sievers EL; Radich JP
Curr Opin Hematol; 2000 Jul; 7(4):212-6. PubMed ID: 10882176
[TBL] [Abstract][Full Text] [Related]
46. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.
Ouyang J; Goswami M; Peng J; Zuo Z; Daver N; Borthakur G; Tang G; Medeiros LJ; Jorgensen JL; Ravandi F; Wang SA
Am J Clin Pathol; 2016 Jun; 145(6):769-77. PubMed ID: 27298396
[TBL] [Abstract][Full Text] [Related]
47. Discriminant function analysis as decision support system for the diagnosis of acute leukemia with a minimal four color screening panel and multiparameter flow cytometry immunophenotyping.
Ratei R; Karawajew L; Lacombe F; Jagoda K; Del Poeta G; Kraan J; De Santiago M; Kappelmayer J; Björklund E; Ludwig WD; Gratama JW; Orfao A;
Leukemia; 2007 Jun; 21(6):1204-11. PubMed ID: 17410192
[TBL] [Abstract][Full Text] [Related]
48. Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry.
Alm SJ; Engvall C; Asp J; Palmqvist L; Abrahamsson J; Fogelstrand L
Int J Lab Hematol; 2017 Apr; 39(2):121-128. PubMed ID: 28004528
[TBL] [Abstract][Full Text] [Related]
49. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia.
Campana D; Coustan-Smith E
Best Pract Res Clin Haematol; 2002 Mar; 15(1):1-19. PubMed ID: 11987913
[TBL] [Abstract][Full Text] [Related]
50. [Advances in minimal residual disease detection with flow cytometry in childhood acute myeloid leukemia].
Feng JH; Xu XJ; Tang YM
Zhonghua Er Ke Za Zhi; 2013 Mar; 51(3):231-4. PubMed ID: 23751588
[No Abstract] [Full Text] [Related]
51. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels.
Inoue K; Ogawa H; Yamagami T; Soma T; Tani Y; Tatekawa T; Oji Y; Tamaki H; Kyo T; Dohy H; Hiraoka A; Masaoka T; Kishimoto T; Sugiyama H
Blood; 1996 Sep; 88(6):2267-78. PubMed ID: 8822948
[TBL] [Abstract][Full Text] [Related]
52. Techniques for detection of minimal residual disease.
Carlo-Stella C; Mangoni L; Dotti GP; Rizzoli V
Leuk Lymphoma; 1995; 18 Suppl 1():75-80. PubMed ID: 7496360
[TBL] [Abstract][Full Text] [Related]
53. [Detection of Minimal Residual Disease in Acute Myeloid Leukemia by Multi-color Flow Cytometry].
He C; Zhang QT; Tang P; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):341-345. PubMed ID: 35395960
[TBL] [Abstract][Full Text] [Related]
54. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
55. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
[TBL] [Abstract][Full Text] [Related]
56. The role of multiparametric flow cytometry in the detection of minimal residual disease in acute leukaemia.
Lee D; Grigoriadis G; Westerman D
Pathology; 2015 Dec; 47(7):609-21. PubMed ID: 26517623
[TBL] [Abstract][Full Text] [Related]
57. [Research progress on minimal residual disease in acute leukemia detected by multiparametric flow cytometry].
Jing H; Feng R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):847-51. PubMed ID: 24989307
[TBL] [Abstract][Full Text] [Related]
58. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.
Vidriales MB; Pérez JJ; López-Berges MC; Gutiérrez N; Ciudad J; Lucio P; Vazquez L; García-Sanz R; del Cañizo MC; Fernández-Calvo J; Ramos F; Rodríguez MJ; Calmuntia MJ; Porwith A; Orfao A; San-Miguel JF
Blood; 2003 Jun; 101(12):4695-700. PubMed ID: 12586618
[TBL] [Abstract][Full Text] [Related]
59. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
San Miguel JF; Martínez A; Macedo A; Vidriales MB; López-Berges C; González M; Caballero D; García-Marcos MA; Ramos F; Fernández-Calvo J; Calmuntia MJ; Diaz-Mediavilla J; Orfao A
Blood; 1997 Sep; 90(6):2465-70. PubMed ID: 9310499
[TBL] [Abstract][Full Text] [Related]
60. Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.
Tomlinson B; Lazarus HM
Expert Rev Hematol; 2017 Jun; 10(6):563-574. PubMed ID: 28475434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
